In order to show proof of principle for therapeutic inhibition of YAP-TEAD signaling via verteporfin, an FDA-approved drug for the treatment of macular degeneration, we utilized in vitro, in vivo and ex vivo assays utilizing human tissue. This evidence concerns the gene YAP1 and macular degeneration.